Company news
Coiled Therapeutics Plc (LSE:COIL) news
Coiled Therapeutics Plc news releases on 6ix. Latest, Sep 27, 2024: Interim Results to 30 June 2024
Press releases — page 2
Interim Results to 30 June 2024
September 27, 2024
Grant of Japan MK Cell Patent
September 23, 2024
STAT-6 siRNA Demonstrates Efficacy in Immunology
September 19, 2024
Grant of MK Cell Patent & Licencing Update
September 2, 2024
Appointment of Broker
June 20, 2024
Issue of Convertible Loan Notes & Board Changes
May 23, 2024
Annual Report & Financial Statements - 31 Dec 2023
April 26, 2024
Response to Share Price Movement
April 5, 2024
Positive Results: Midkine mRNA and STAT-6 siRNA
March 11, 2024
Operations Update
February 6, 2024
Change of Auditor
November 24, 2023
Significant Mesodermal Killer Cell Milestone
November 6, 2023
Interim Results to 30 June 2023
September 27, 2023
Investor Presentation via Investor Meet Company
September 22, 2023
Expansion of Patent Portfolio
August 14, 2023
Development of New Novel siRNA Therapeutics
August 7, 2023
AGM Statement
June 29, 2023
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
June 22, 2023
Antibody Program Results & Orphan Drug Indication
June 19, 2023
Anti-Cancer MDK mRNA - Positive in vitro Results
June 13, 2023
Restoration of Trading
June 7, 2023
Annual Report & Financial Statements - 31 Dec 2022
June 5, 2023
Suspension of Trading Pending 2022 Annual Report
May 2, 2023
Confirmation of No Exposure to Silicon Valley Bank
March 13, 2023
Creation of New Novel Family of mRNA Therapeutics
March 8, 2023
Formation of Scientific Advisory Board
March 6, 2023
Company Presentation
March 1, 2023
Randox Licence and Royalty Agreement
February 20, 2023
MDK Oncology Antibodies Demonstrate In-Vivo Safety
January 24, 2023
Appointment of Auditor
January 16, 2023
Presentation of Midkine Oligonucleotide Program
December 5, 2022
Resignation of Auditor
December 1, 2022
Midkine Antibody Program - Festival of Biologics
October 25, 2022
ROQ Presents Study Results at the ESGCT Conference
October 11, 2022
Interim Results to 30 June 2022
September 23, 2022
Board and Management Appointments
September 16, 2022
Notice of Admission
September 15, 2022
Publication of Prospectus
September 13, 2022
Pre-clinical Program & Transaction Update
August 11, 2022
Appointment of Joint Broker
July 20, 2022
Commencement of Trading on US OTCQB Venture Market
July 15, 2022
Result of AGM
June 30, 2022
Update on Acquisition of Oncogeni and Placing
June 23, 2022
Issue of Warrants
June 22, 2022
Notice of AGM - Correction
June 13, 2022
Pre-clinical Update
June 7, 2022
Annual Report & Financial Statements
May 11, 2022
Non-Executive Director Appointment
April 20, 2022
Board Appointment
April 5, 2022
Patent Filed - New Drug Class Targeting Midkine
March 21, 2022